COMPANY
A&G Pharmaceutical, Inc.
A&G PHARMACEUTICAL, INC. is listed on ClinicalTrials.gov as the lead sponsor of 1 study; the most recently updated is “First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies” (Phase 1, recruiting), in Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer. From public records Source · Oct 12, 2026
Timeline
- Trial start 1: First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | 1 | Recruiting | Feb 14, 2022 | 2026-06 (estimated) |